CINCINNATI, March 27, 2017 (GLOBE NEWSWIRE) -- Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the further expansion of the JetSeq™ portfolio for Next Generation Sequencing (NGS) sample preparation.
The new JetSeq™ Library Quantification Kit is a qPCR-based assay that provides fast, accurate and sensitive quantification of adaptor-ligated DNA fragments during the preparation of Illumina compatible NGS libraries. The JetSeq™ Library Quantification Kit relies on SYBR®1 Green I for detection and contains all of the components required for library quantification, including dilution buffer, P5 and P7 adapter primers and six pre-diluted DNA standards to minimize pipetting, reduce variability and thereby increase reproducibility. The kit has sufficient standards to quantify eighteen libraries on individual plates or up to seventy-six libraries when multiple libraries are quantified on the same plate.
Marco Calzavara, President of Bioline commented, “The release of the new JetSeq™ Library Quantification Kit compliments the JetSeq™ Library preparation kits that Bioline launched last month, moving us even further into the NGS space. The kit builds on our extensive knowledge in qPCR, providing a fast, sensitive and reliable solution to determine library concentrations, giving customers confidence in the cluster density loaded on Illumina sequencing platforms.”
Richard L. Eberly, President, Chief Commercial Officer, stated, “We are pleased to announce the release of the new JetSeq™ Library Quantification Kit; this is an important addition to our ever-increasing portfolio of NGS products and gives our life science customers greater confidence in the quantification of their sequencing libraries. The further development of the JetSeq™ family shows our commitment, not just to the continued development and expansion of products from Bioline, but also to our customers, giving them a greater support around this fast-growing market.”
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic test kits, rare reagents, specialty biologicals and components. Utilizing a variety of methods, our diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as infections and lead poisoning. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company's diagnostic products are designed to enhance patient well-being while reducing the total outcome costs of health care. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections and blood lead level testing. In addition, Meridian is a supplier of rare reagents, specialty biologicals and components used by organizations in the life science and agribio industries engaged in research and by companies as components in the manufacture of diagnostics. The Company markets its products and technologies to hospitals, reference laboratories, research centers, diagnostics manufacturers and agribio companies in more than 70 countries around the world. The Company’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian's website address is www.meridianbioscience.com.
FOR ADDITIONAL INFORMATION:
For more information about Bioline, please visit http://www.bioline.com.
1 SYBR is a registered trademark of Thermo Fisher Scientific.
Richard L. Eberly
President, Chief Commercial Officer
Meridian Bioscience, Inc.
Meridian Bioscience, Inc.